Our Strategy

We believe that oral small molecule therapeutics could overcome the challenges associated with biologic and peptide drugs, which can be costly and inconvenient for patients. Improved patient access could be particularly significant for common chronic diseases involving the endocrine and pulmonary systems. We believe that our drug discovery platform can capitalize on the advantages of highly selective potent small molecule therapeutics, such as potentially enhanced clinical activity and improved safety profile due to lower and more convenient dosing requirements and lower costs.

Our current development programs are focused on developing small molecule therapeutics that modulate G protein-coupled receptors (GPCRs) for the treatment of metabolic, inflammatory and fibrotic conditions. Our pipeline is currently made up of three development programs. The candidate we selected for clinical development, LMNL6511, a selective antagonist for the GPR84 receptor, has recently completed a first-in-humans Phase 1 SAD/MAD clinical trial in the UK and has recently commenced a Phase 1b multiple dose placebo-controlled clinical trial of LMNL6511 in healthy subjects. We are also developing potential OXER1 antagonists and GPR40 agonists, both of which are at the preclinical stage. 

Our goal is to leverage our drug discovery and project management expertise to develop distinctive novel small molecule therapeutics to treat the complex biology of metabolic, inflammatory and fibrotic diseases to address a wide range of significant unmet needs via partnering opportunities.